These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 21178654

  • 1. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.
    Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA, Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators.
    Pediatr Infect Dis J; 2011 May; 30(5):402-7. PubMed ID: 21178654
    [Abstract] [Full Text] [Related]

  • 2. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P.
    Clin Infect Dis; 2010 Sep 15; 51(6):668-77. PubMed ID: 20687838
    [Abstract] [Full Text] [Related]

  • 3. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D.
    Vaccine; 2011 Dec 09; 30(1):35-41. PubMed ID: 22063386
    [Abstract] [Full Text] [Related]

  • 4. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients.
    Bickel M, von Hentig N, Wieters I, Khaykin P, Nisius G, Haberl A, Stephan C, Herrmann E, Doerr HW, Brodt HR, Allwinn R.
    Clin Infect Dis; 2011 Jan 01; 52(1):122-7. PubMed ID: 21148530
    [Abstract] [Full Text] [Related]

  • 5. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.
    Vaccine; 2010 Jan 08; 28(3):849-57. PubMed ID: 19835828
    [Abstract] [Full Text] [Related]

  • 6. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N.
    Pediatr Infect Dis J; 2012 Apr 08; 31(4):e59-65. PubMed ID: 22418661
    [Abstract] [Full Text] [Related]

  • 7. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.
    Pediatr Infect Dis J; 2009 Jul 08; 28(7):563-71. PubMed ID: 19561422
    [Abstract] [Full Text] [Related]

  • 8. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.
    Vaccine; 2012 Jul 13; 30(33):5030-7. PubMed ID: 22472791
    [Abstract] [Full Text] [Related]

  • 9. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I.
    Vaccine; 2010 Apr 19; 28(18):3076-9. PubMed ID: 20193791
    [Abstract] [Full Text] [Related]

  • 10. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
    Block SL, Ruiz-Palacios GM, Guerrero ML, Beygo J, Sales V, Holmes SJ.
    Pediatr Infect Dis J; 2012 Jul 19; 31(7):e92-8. PubMed ID: 22481427
    [Abstract] [Full Text] [Related]

  • 11. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M.
    Vaccine; 2009 Oct 23; 27(45):6291-5. PubMed ID: 19840662
    [Abstract] [Full Text] [Related]

  • 12. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children.
    Meier S, Bel M, L'huillier A, Crisinel PA, Combescure C, Kaiser L, Grillet S, Pósfay-Barbe K, Siegrist CA, H1N1 Epidemiology Study Group of Geneva.
    Vaccine; 2011 Apr 27; 29(19):3548-57. PubMed ID: 21419775
    [Abstract] [Full Text] [Related]

  • 13. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, Reeves-Hoché MK, Denis M.
    Vaccine; 2011 Feb 11; 29(8):1569-75. PubMed ID: 21219979
    [Abstract] [Full Text] [Related]

  • 14. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients.
    Meyer S, Adam M, Schweiger B, Ilchmann C, Eulenburg C, Sattinger E, Runte H, Schlüter M, Deuse T, Reichenspurner H, Costard-Jäckle A.
    Transplantation; 2011 May 15; 91(9):1031-5. PubMed ID: 21358365
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.
    Phongsamart W, Sirisanthana V, Wittawatmongkol O, Maleesatharn A, Sudjaritruk T, Chearskul P, Aurpibul L, Sirisanthana T, Chokephaibulkit K.
    Vaccine; 2011 Nov 03; 29(47):8705-11. PubMed ID: 21893147
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, Hsieh YC, Lin TY, Huang LM.
    Vaccine; 2010 Aug 16; 28(36):5864-70. PubMed ID: 20600484
    [Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
    Palma P, Romiti ML, Bernardi S, Pontrelli G, Mora N, Santilli V, Tchidjou HK, Aquilani A, Cotugno N, Alghisi F, Lucidi V, Rossi P, Douagi I.
    Biologicals; 2012 Mar 16; 40(2):134-9. PubMed ID: 22261282
    [Abstract] [Full Text] [Related]

  • 18. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S, Tagliaferri L, Daleno C, Valzano A, Picciolli I, Tel F, Prunotto G, Serra D, Galeone C, Plebani A, Principi N.
    Vaccine; 2011 Feb 11; 29(8):1677-82. PubMed ID: 21199699
    [Abstract] [Full Text] [Related]

  • 19. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.
    Vaccine; 2011 Sep 16; 29(40):6888-93. PubMed ID: 21803100
    [Abstract] [Full Text] [Related]

  • 20. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.
    Pediatrics; 2011 May 16; 127(5):e1161-8. PubMed ID: 21464195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.